A Phase I Study of the Potent AKT Inhibitor MK-2206 in Combination With Carboplatin and Paclitaxel, Docetaxel or Erlotinib in Patients With Advanced Solid Tumours

被引：0
|
作者：
Molife, L. R. [1 ]
Minton, S. [2 ]
Vitfell-Pedersen, J. [1 ]
Chen, E. [3 ]
Sullivan, D. [2 ]
Yan, L. [4 ]
Zernhelt, A. M. [4 ]
Siu, L. [3 ]
de Bono, J. S. [1 ]
Tolcher, A. W. [5 ]
机构：
[1] Royal Marsden Hosp, Inst Canc Res, Drug Dev Unit, Sutton, Surrey, England
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[3] Univ Hlth Network, Princess Margaret Hosp, Toronto, ON, Canada
[4] Merck Sharp & Dohme Ltd, Merck Res Labs Clin Oncol, Philadelphia, PA USA
[5] S Texas Accelerated Res Therapeut START Ctr Canc, San Antonio, TX USA
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)70814-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S144 / S145
页数：2
相关论文
共 50 条
  • [1] Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
    L Rhoda Molife
    Li Yan
    Joanna Vitfell-Rasmussen
    Adriane M Zernhelt
    Daniel M Sullivan
    Philippe A Cassier
    Eric Chen
    Andrea Biondo
    Ernestina Tetteh
    Lillian L Siu
    Amita Patnaik
    Kyriakos P Papadopoulos
    Johann S de Bono
    Anthony W Tolcher
    Susan Minton
    Journal of Hematology & Oncology, 7
  • [2] Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
    Molife, L. Rhoda
    Yan, Li
    Vitfell-Rasmussen, Joanna
    Zernhelt, Adriane M.
    Sullivan, Daniel M.
    Cassier, Philippe A.
    Chen, Eric
    Biondo, Andrea
    Tetteh, Ernestina
    Siu, Lillian L.
    Patnaik, Amita
    Papadopoulos, Kyriakos P.
    de Bono, Johann S.
    Tolcher, Anthony W.
    Minton, Susan
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
  • [3] A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST)
    Tolcher, A. W.
    Yap, T. A.
    Fearen, I.
    Taylor, A.
    Carpenter, C.
    Brunetto, A. T.
    Beeram, M.
    Papadopoulos, K.
    Yan, L.
    de Bono, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] PHASE 1 STUDY OF THE SELECTIVE AKT INHIBITOR MK-2206 IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Tanabe, Y.
    Doi, T.
    Tamura, K.
    Yonemori, K.
    Kodaira, M.
    Fuse, N.
    Bando, H.
    Maeda, Y.
    Shimamoto, T.
    Ohtsu, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 164 - 164
  • [5] A phase I study of MK-2206 in combination with lapatinib in patients (pts) with advanced solid tumors.
    Wisinski, Kari Braun
    Tevaarwerk, Amye
    Bell, Maria
    Burkard, Mark E.
    Eickhoff, Jens C.
    Wilding, George
    LoConte, Noelle K.
    Traynor, Anne M.
    Hoang, Tien
    Heideman, Jennifer
    Kolesar, Jill
    Liu, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer
    Murphy, Adrian G.
    Zahurak, Marianna
    Shah, Mirat
    Weekes, Colin D.
    Hansen, Aaron
    Siu, Lillian L.
    Spreafico, Anna
    LoConte, Noelle
    Anders, Nicole M.
    Miles, Tearra
    Rudek, Michelle A.
    Doyle, L. Austin
    Nelkin, Barry
    Maitra, Anirban
    Azad, Nilofer S.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (06): : 1178 - 1188
  • [7] A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors
    Mehnert, Janice M.
    Kaveney, Amanda D.
    Malhotra, Jyoti
    Spencer, Kristen
    Portal, Daniella
    Goodin, Susan
    Tan, Antoinette R.
    Aisner, Joseph
    Moss, Rebecca A.
    Lin, Hongxia
    Bertino, Joseph R.
    Gibbon, Darlene
    Doyle, Laurence A.
    White, Eileen P.
    Stein, Mark N.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 899 - 907
  • [8] A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors
    Janice M. Mehnert
    Amanda D. Kaveney
    Jyoti Malhotra
    Kristen Spencer
    Daniella Portal
    Susan Goodin
    Antoinette R. Tan
    Joseph Aisner
    Rebecca A. Moss
    Hongxia Lin
    Joseph R. Bertino
    Darlene Gibbon
    Laurence A. Doyle
    Eileen P. White
    Mark N. Stein
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 899 - 907
  • [9] Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
    Doi, Toshihiko
    Tamura, Kenji
    Tanabe, Yuko
    Yonemori, Kan
    Yoshino, Takayuki
    Fuse, Nozomu
    Kodaira, Makoto
    Bando, Hideaki
    Noguchi, Kazuo
    Shimamoto, Takashi
    Ohtsu, Atsushi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (02) : 409 - 416
  • [10] Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
    Toshihiko Doi
    Kenji Tamura
    Yuko Tanabe
    Kan Yonemori
    Takayuki Yoshino
    Nozomu Fuse
    Makoto Kodaira
    Hideaki Bando
    Kazuo Noguchi
    Takashi Shimamoto
    Atsushi Ohtsu
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 409 - 416
12345